SIGN UP FOR SUPPORT

Share
NEWS ABOUT DARZALEX®

PATIENT SITE

Discover

More Possibilities

A new option for patients with multiple myeloma: DARZALEX® can now be used in combination with Revlimid® (lenalidomide) and dexamethasone or Velcade® (bortezomib) and dexamethasone in patients who have received at least one prior medicine.

How does DARZALEX® work?
  • DARZALEX® is not chemotherapy. DARZALEX® is a monoclonal antibody that works with your immune system. Monoclonal antibodies work by attaching themselves to multiple myeloma cells in your body and directly killing them, and/or signaling your immune system to destroy them
  • DARZALEX® finds and attaches to a protein called CD38, which is present on the surface of cells, including high numbers on myeloma cells
RESULTS SEEN IN CLINICAL TRIALS
  • The main goal of the study was to measure the length of time patients live without their multiple myeloma getting worse or their passing away from any cause
    • Another goal was to measure response rate, which is the percentage of patients who responded to treatment. Talk to your doctor about how response is measured
  • The majority of patients responded to the following DARZALEX® combination treatments:
    • ​DARZALEX® was studied in combination with Revlimid® and dexamethasone (Rd) vs Rd alone in 569 patients who had received a minimum of 1 prior treatment
      • 9 out of 10 patients responded to DARZALEX® + Rd vs 7 out of 10 with Rd alone
    • DARZALEX® was studied in combination with Velcade® and dexamethasone (Vd) vs Vd alone in 498 patients who had received a minimum of 1 prior treatment
      • Almost 8 out of 10 patients responded to DARZALEX® + Vd vs almost 6 out of 10 with Vd alone
  • DARZALEX® combination treatments reduced patients’ risk of their disease getting worse or their passing away from any cause by more than 60%

Sign up to receive updates and more information.

Click here if you are a healthcare professional.

Revlimid® is a registered trademark of Celgene Corporation.
Velcade® is a registered trademark of Millennium Pharmaceuticals, Inc.

Sign up for ongoing communications

Register with our Janssen CarePath support program for DARZALEX® and receive ongoing communications such as e-mails, and calls from DARZALEX® Clinical Nurses during your treatment journey—whether you are on DARZALEX® or just want to learn more.

*Required field

Please tell us about yourself so that we can provide the information about DARZALEX® that means the most to you: 

*Where can we send you information?

We are asking for your phone number because a DARZALEX® Clinical Nurse will contact you during your treatment journey. It will be used only for communications associated with this program.

*Please select a preferred 30-minute window between 8:00 am and 8:00 pm ET for us to call


08:30 am

Information Collection Terms
By providing your information above, you are requesting to register your participation with www.darzalex.com. The information you provide will be used by Janssen Biotech, Inc., our affiliates, and our service providers to satisfy this purpose, and to research, develop, and improve products and services. You can stop receiving these communications by visiting www.darzalex.com/unsubscribe. The information you provide will be further governed by the Janssen Biotech, Inc., Privacy Policy. By providing the information and selecting the SUBMIT button, you indicate that you read, understand, and agree to these terms.